Hisamitsu Pharmaceutical Co., Inc.

Tokyo Stock Exchange 4530.T

Hisamitsu Pharmaceutical Co., Inc. EBIT for the year ending February 29, 2024: USD 128.00 M

Hisamitsu Pharmaceutical Co., Inc. EBIT is USD 128.00 M for the year ending February 29, 2024, a 50.36% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Hisamitsu Pharmaceutical Co., Inc. EBIT for the year ending February 28, 2023 was USD 85.13 M, a 4.84% change year over year.
Hisamitsu Pharmaceutical Co., Inc. EBIT for the year ending February 28, 2022 was USD 81.19 M, a -18.93% change year over year.
Hisamitsu Pharmaceutical Co., Inc. EBIT for the year ending February 28, 2021 was USD 100.16 M, a -52.32% change year over year.
Hisamitsu Pharmaceutical Co., Inc. EBIT for the year ending February 29, 2020 was USD 210.06 M, a 5.04% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Tokyo Stock Exchange: 4530.T

Hisamitsu Pharmaceutical Co., Inc.

CEO	Mr. Kazuhide Nakatomi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	408, Tashiro Daikan-machi
Employees	2,759
Sector	Healthcare
Industries Pharmaceuticals Automotive Parts Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Perfumes & Fragrances Personal Care

Description

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

Key trends

Past 5 years